MSB

2.51%

97.0¢ mesoblast limited

I'm not saying the cells don't work.I'm saying...

First 430 Last

Share
Profile

Follow
DocMcstuffins

7,812 Posts.

1344

18/03/24

09:47

Post #: 72934398
Share

Originally posted by Leo65: ↑

With an appropriate post hoc statistical test we can reduce the risk of type I error (this error is inflated in multiple comparison between several subgroups) and also obtain acceptable statistical power, which of course depends on the sample size and data variance in subgroups. Brief, choosing an appropriate multi comparison test and having high number of data points in subgroups and low variance make the post hoc statistical analysis scientifically valid.

I found below a good summary of what we need to consider in post hoc analysis. In our case showing cells are more efficient in treatment of patients with higher inflammation (e.g, higher IL-6) is highly plausible and correlated with the proposed mechanism of action.

“Reporting of treatment effects on subgroups of patients are common in the medical literature. Although knowing how well a new treatment works in patients with a specific biomarker or a specific combination of disease stage and histology are important for the patients and their clinicians to make informed treatment decisions, it is important to be cautious when interpreting the results of subgroup analyses. Common challenges with subgroup analyses include poor definitions, low statistical power, and inflated type I error due to multiple hypotheses testing. The decision to conduct a subgroup analysis should depend biological justification or on evidence of treatment heterogeneity from existing preliminary data. When a large number of unplanned subgroup analyses are conducted, the treatment may spuriously appear to be effective in one or more subgroups. One should always assess the validity of subgroup analysis results based on biological plausibility, sample size for the subgroup, proper type I error control and power.”

Expand

I'm not saying the cells don't work.

I'm saying they havent been properly proven to work. They've generated hypotheses, but they haven't confirmed any of them with an independent RCT.

And it's a bit concerning they only seem to get significant results when they are analysing subgroups - if they managed to do an RCT that met its primary endpoint things would be looking much better.

Last edited by DocMcstuffins: 18/03/24

MSB Price at posting: 35.5¢ Sentiment: Sell Disclosure: Not Held
3 Upvote

0 Great analysis

Reply

Top Stories

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

WGX

Westgold sets its sights on top five producer status through merger with Karora

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

GRX

GreenX picks up prospective copper project in Germany

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

There are more pages in this discussion • 120 more messages in this thread...

First 430 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 97.0¢		Change -0.025(2.51%)		Mkt cap ! $1.107B

Open	High	Low	Value	Volume
97.0¢	$1.01	96.5¢	$7.757M	7.884M

Buyers (Bids)

No.	Vol.	Price($)
10	274918	97.0¢

Sellers (Offers)

Price($)	Vol.	No.
97.5¢	974	1

View Market Depth

No.	Vol.	Price($)
6	103162	0.970
5	34741	0.965
11	125566	0.960
1	500	0.955
22	165429	0.950

Price($)	Vol.	No.
0.975	974	1
0.990	10204	1
1.000	14000	1
1.010	2877	1
1.015	60000	1

Last trade - 16.10pm 02/08/2024 (20 minute delay)

MSB (ASX) Chart

I'm not saying the cells don't work.I'm saying...

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Venture to sniff out high-grade REE targets at Jupiter project, WA

Westgold sets its sights on top five producer status through merger with Karora

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

GreenX picks up prospective copper project in Germany

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I&apos;m not saying the cells don&apos;t work.I&apos;m saying...

Top Stories

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Venture to sniff out high-grade REE targets at Jupiter project, WA

Westgold sets its sights on top five producer status through merger with Karora

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Is oil undervalued?

GreenX picks up prospective copper project in Germany

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I'm not saying the cells don't work.I'm saying...